Cited by 619Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Open access

Burnett, Alan K., Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert K., Wheatley, Keith·2007·Cancer

DOI 10.1002/cncr.22496

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily for 10 days) or hydroxyurea with or without all‐trans retinoic acid (ATRA). RESULTS: Low‐dose ara‐C produced a better remission rate (18% vs 1%; odds ratio [OR], 0.15; 95% confidence interval [95% CI], 0.06–0.37; P = .00006) and better overall survival (OR, 0.60; 95% CI, 0.44–0.81; P = .0009), which was accounted for by the achievement of complete remission (CR) (duration of CR: 80 weeks vs 10 weeks for patients with no CR). Patients who had adverse cytogenetics did not benefit. ATRA had no effect. Toxicity scores or supportive care requirements did not differ between the treatment arms. CONCLUSIONS: Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low‐dose ara‐C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group. [See editorial on pages 000–000, this issue.] Cancer 2007 © 2007 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.22496

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson, B. D., Jasperse, D. M., Simon, R. M., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 210
Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
Housset, M., Daniel, M., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 189
Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 179
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid
Andreeff, M., Jiang, S., Zhang, X., Konopleva, M. Y., Estrov, Z. E., Snell, V., Xie, Z., Okcu, M., Sanchez‐Williams, G., Dong, J., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401573 · Cited by 153
Sexual functioning morbidity among cancer survivors. Current status and future research directions
Andersen, B. L. (1985) · Cancer · doi:10.1002/1097-0142(19850415)55:8 · Cited by 147

Show all 26 references

Sorted by citations

Items 401–500 of 619

Frontline Therapy of AML: Should the Older Patient be Treated Differently?
Foran, J. M. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0211-8 · Cited by 7
Phase I Study of Clofarabine in Adult Patients with Acute Myeloid Leukemia in Japan
Suzuki, T., Yamauchi, T., Ando, K., Nagai, T., Kakihana, K., Miyata, Y., Uchida, T., Tabata, Y., & Ogura, M. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt155 · Cited by 7
Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia
Wang, B., Guan, W. P., Lv, N., Li, T., Yu, F., Huang, Y., Wang, Y., Li, L., & Yu, L. (2021) · Hematology · doi:10.1080/16078454.2021.1921434 · Cited by 7
How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia
Moore, J. W., Torres, N., Superdock, M., Mendler, J. H., & Loh, K. P. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00991-z · Cited by 7
Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
Roldán, A., Paganini, J. A. V., Moreno, M., Mesa, E. G., Moreno, A. S. V., Núñez‐Torrón, C., & García, R. H. (2022) · Clinical Case Reports · doi:10.1002/ccr3.6116 · Cited by 7
The contribution of randomized trials to the cure of haematological disorders from B radford H ill onwards
Hills, R. K. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09213.x · Cited by 7
Self-citation
Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study
Gemünden, C., Benz, R. A., Senn, O., Goede, J. S., Manz, M. G., & Gerber, B. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.09.003 · Cited by 7
Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia
Sekeres, M. A., & Gerds, A. T. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.009 · Cited by 7
Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia
Seymour, J. F., Döhner, H., Minden, M. D., Stone, R. M., Gambini, D., Dougherty, D., Beach, C. L., Weaver, J., & Dombret, H. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1243680 · Cited by 7
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
Tiong, I. S., Tan, P. T., McManus, J. F., Cummings, N., Sadawarte, S., Catalano, J. V., Hills, R. K., & Wei, A. H. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1334122 · Cited by 7
Self-citation
Acute myeloid leukemia in the elderly: what constitutes treatment value?
Nabhan, C., Kamat, S., & Kish, J. K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1520992 · Cited by 7
The Relevance of Aurora Kinase Inhibition in Hematological Malignancies
Machado, C. B., da Silva, E. L., Nogueira, B. M. D., da Silva, J. B. S., de Moraes, M. O., Montenegro, R. C., de Moraes, M. E. A., & Moreira-Nunes, C. A. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10016 · Cited by 7
Arsenic and Old Lace: Novel Approaches in Elderly Patients With Acute Myeloid Leukemia
Roboz, G. J. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.07.005 · Cited by 7
Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival
Arthur, C. K., Jeffrey, A., Yip, E., Katsioulas, V., Nalpantidis, A., Kerridge, I., Greenwood, M. J., Coyle, L. A., Mackinlay, N. J., Fay, K. C., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1697876 · Cited by 7
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal, S., Kowalski, A., Schiffer, M., Zhao, J. C., Bewersdorf, J. P., & Zeidan, A. M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1876559 · Cited by 10
High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia
Shacham‐Abulafia, A., Itchaki, G., Yeshurun, M., Paul, M., Peck, A., Leader, A., Shpilberg, O., Ram, R., & Raanani, P. (2015) · Acta Haematologica · doi:10.1159/000437131 · Cited by 7
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
Aldoss, I. T., & Marcucci, G. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.09.03 · Cited by 7
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy
Loke, J. C. T., Metzner, M., Boucher, R. H., Jackson, A. E., Hopkins, L. M., Pavlů, J., Tholouli, E., Drummond, M. W., Peniket, A., Bishop, R., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17823 · Cited by 6
The blind men and the AML elephant: can we feel the progress?
Tauro, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.33 · Cited by 6
Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?
Foran, J. M. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.09.008 · Cited by 6
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases
Feld, J., Silverman, L. R., & Navada, S. C. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.007 · Cited by 6
Acute Myeloid Leukemia in the Elderly Patient: New Strategies
Thomas, X. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0006-7 · Cited by 6
Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions
Rosenblat, T. L., & Jurcic, J. G. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.007 · Cited by 6
Treatment of Elderly Acute Myeloid Leukemia Patients
Motyckova, G., & Stone, R. M. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0162-4 · Cited by 6
Identifying effective drug combinations for patients with acute myeloid leukemia
Yilmaz, M. E., Kadia, T. M., & Ravandi, F. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1782749 · Cited by 6
The fludarabine, cytarabine, and granulocyte colony‐stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline‐based therapy for the treatment of acute myeloid leukemia for patients with pre‐existing cardiac disease
Saini, L., Brandwein, J. M., Turner, R., Larratt, L. M., Hamilton, M. A., Peters, A., Wu, C. M., Zhu, N. Y., Patterson, J. M., Bolster, L., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12757 · Cited by 6
Improving outcomes for elderly patients with AML
Russell, N. H. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70450-3 · Cited by 6
Myelodysplastic syndromes and acute myeloid leukemias in the elderly
Mueller, B. U., Seipel, K., & Pabst, T. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.026 · Cited by 5
Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia
Li, C., Chen, H.-Y., Yen, J., Yu, S., Chou, T.-Y., Yeh, S.-W., Chuang, H.-Y., & Huang, F. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13416 · Cited by 5
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
Kantarjian, H. M., Borthakur, G. M., Daver, N. G., Dinardo, C. D., Garcia‐Manero, G., Issa, G. C., Jabbour, E. J., Jain, N., Kadia, T. M., Loghavi, S., et al. (2025) · Cancer · doi:10.1002/cncr.70113 · Cited by 6
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
Relias, V., McBride, A., Newman, M. J., Paul, S., Saneeymehri, S. S., Stanislaus, G., Tobin, J., Hoang, C. J., Ryan, J. C., & Galinsky, I. A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220973737 · Cited by 5
Efficacy of the Combination of Venetoclax and Azacitidine in Elderly of Frail Relapsed/ Refractory Patients with Acute Myeloid Leukemia, First Multi-Institutional Real World Experience from Turkey
Aktimur, S. H. (2020) · International Journal of Hematology and Oncology · doi:10.4999/uhod.204358 · Cited by 5
Advances in the treatment of elderly and frail patients with acute myeloid leukemia
Amadori, S., Principe, M. I. D., & Venditti, A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000124 · Cited by 5
Acute Myeloid Leukemia: Potential for New Therapeutic Approaches Targeting mRNA Translation Pathways
Altman, J. K., & Platanias, L. C. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.23 · Cited by 5
Targeting the FLT3 Mutation in Acute Myeloid Leukaemia
Käyser, S., & Schlenk, R. F. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.02.139 · Cited by 5
Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience
Öneç, B., Okutan, H., Albayrak, M., Can, E. S., Aslan, V., Koluman, B. Ü., Kösemehmetoğlu, Ö. S., & Albayrak, A. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.187369 · Cited by 5
Current treatment preferences in acute myeloid leukemia: a survey in Brazil
Portugal, R. D., & Nucci, M. (2019) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2019.07.005 · Cited by 5
Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia – results from a retrospective Belgian registry study
Meers, S., Bailly, B., Broek, I. V., Malfait, B., Hoorenbeeck, S. V., Geers, J., Braakman, J., van Kouwenhove, M., Doyle, M., Diels, J., et al. (2019) · Acta Clinica Belgica · doi:10.1080/17843286.2019.1665233 · Cited by 5
Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis
Reljic, T., Sehovic, M., Lancet, J. E., Kim, J., Ali, N. E. A., Djulbegović, B., & Extermann, M. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.06.019 · Cited by 5
Treatment Pattern, Financial Burden, and Outcomes in Elderly Patients with Acute Myeloid Leukemia in Korea: A Nationwide Cohort Study
Ha, H., Jeong, Y., Lim, J. H., & Suh, Y. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042317 · Cited by 5
Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial
Pongudom, S., Phinyo, P., Chinthammitr, Y., Charoenprasert, K., Kasyanan, H., Wongyai, K., Purattanamal, J., Panoi, N., & Surawong, A. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.1.147 · Cited by 5
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML
Ambinder, A. J., Norsworthy, K. J., Hernandez, D., Palau, L., Paun, B. C., Duffield, A. S., Chandraratna, R., Sanders, M. E., Varadhan, R., Jones, R. J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587062 · Cited by 5
Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid
Teichler, S., Schlenk, R. F., Strauch, K., Hagner, N., Ritter, M., & Neubauer, A. (2008) · Haematologica · doi:10.3324/haematol.12003 · Cited by 5
The graceful exit or reluctant demise of the older adult with acute myeloid leukemia
Sekeres, M. A., & Gerds, A. T. (2015) · Cancer · doi:10.1002/cncr.29428 · Cited by 5
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML
Ossenkoppele, G. J., & Vyas, P. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01788 · Cited by 5
Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis
Awad, A. A., Shaban, A. Y., Mohammed, F., Marey, M. M., Aldemerdash, M. A., Abbas, A. W., Saeed, O., Saeed, A., Elhady, M. M., Sharabati, I., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01528-5 · Cited by 4
Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review
Gandhi, A. P., Andrick, B. J., Darling, J. O., Truong, T., & Signorelli, J. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.08.005 · Cited by 4
Acute myeloid leukemia in the medically unfit elderly patients
Edmund, J., Thaliath, L. J., & Meleveedu, K. S. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107306 · Cited by 4
Traitement des syndromes myélodysplasiques
Fenaux, P., & Adès, L. (2009) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(09)74251-0 · Cited by 4
The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy
Yanada, M., Okamoto, A., Inaguma, Y., Tokuda, M., Morishima, S., Kanie, T., Yamamoto, Y., Mizuta, S., Akatsuka, Y., Okamoto, M., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1786-0 · Cited by 4
Older patients with acute myeloid leukemia
Yee, K. W. L., & Keating, A. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.68 · Cited by 4
Quality of Life Issues in Elderly Acute Myeloid Leukemia Patients
Saini, L., Alibhai, S. M. H., & Brandwein, J. M. (2011) · Aging Health · doi:10.2217/ahe.11.32 · Cited by 4
Efficacy of Tosedostat, a Novel, Oral Agent for Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia: A Review of The Phase II OPAL Trial
Mathisen, M. S., & Ravandi, F. (2012) · Future Oncology · doi:10.2217/fon.12.17 · Cited by 4
The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia
Kell, J. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162099 · Cited by 4
Improving the Transition to Palliative Care for Patients With Acute Leukemia
Hopkins, B., Gold, M., Wei, A. H., & Grigoriadis, G. (2016) · Cancer Nursing · doi:10.1097/ncc.0000000000000368 · Cited by 4
A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia
He, F. C., Sapkota, S., Parker, S., DeFor, T. E., Warlick, E. D., Üstün, C., Eckfeldt, C. E., Rashidi, A., Kurtzweil, A. J., Weisdorf, D. J., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1433297 · Cited by 4
Diagnostic and Prognostic Significance of Serum Cd26 Level In Asian Women With High-Grade Serous Ovarian Carcinoma
Shao, S., Wang, C., Tian, J., Zhang, H., Wang, S., & Du, Y. (2019) · Future Oncology · doi:10.2217/fon-2018-0725 · Cited by 4
The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis
Huang, X., Liu, Y., Liu, R., Zou, X., & Yang, H. (2023) · Hematology · doi:10.1080/16078454.2023.2274149 · Cited by 4
Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future
Hills, R. K. (2019) · British Journal of Haematology · doi:10.1111/bjh.16357 · Cited by 4
Self-citation
Acute Leukemia in Patients Sixty Years of Age and Older
Leger, C. S., Leitch, H. A., Galbraith, P. F., Li, C. H., & Vickars, L. M. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818a6c93 · Cited by 4
MRC trials in acute myeloblastic luekemia: Where have we got to?
Burnett, A. K. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701706139 · Cited by 4
Self-citation
When a gold standard is made of tin
Schiller, G. J. (2010) · Blood · doi:10.1182/blood-2010-08-300566 · Cited by 4
Acute Myeloid Leukemia in the Elderly
Thomas, X. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.6 · Cited by 4
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML
Tenti, E., Papayannidis, C., Marconi, G., Parisi, S., Simonetti, G., Paolini, S., Sartor, C., Ottaviani, E., Testoni, N., & Martinelli, G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258056 · Cited by 4
Diagnostik und Therapie der akuten myeloischen Leukämie
Röllig, C. (2019) · Der Internist · doi:10.1007/s00108-019-0562-2 · Cited by 4
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Naoe, T. (2020) · PubMed Central · doi:10.18999/nagjms.82.2.151 · Cited by 4
Laromustine (cloretazine)
Vey, N., & Giles, F. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003621232 · Cited by 4
Evaluation of prognostic factors in AML
Rowe, J. M. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.09.003 · Cited by 4
What Is Better for Older Patients With Acute Myeloid Leukemia?
Ferrara, F., & Musto, P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2219 · Cited by 4
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
Berdel, A. F., Koch, R., Gerß, J., Hentrich, M., Peceny, R., Bartscht, T., Steffen, B., Bischoff, M., Spiekermann, K., Angenendt, L., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05025-0 · Cited by 3
Induction treatment of acute myeloid leukemia in an elderly patient with intramarrow injection/administration of cytarabine: first report of a case
Islam, A. (2015) · Clinical Case Reports · doi:10.1002/ccr3.429 · Cited by 3
Decitabine for the treatment of acute myeloid leukemia
Bryan, J., Kantarjian, H. M., & Jabbour, E. J. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.819288 · Cited by 3
How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?
Tvedt, T. H. A., Reikvam, H., Aasebø, E., Hernandez-Valladares, M., Berven, F. S., Selheim, F., & Bruserud, Ø. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2016.1236659 · Cited by 3
Behandling av akutt myelogen leukemi hos eldre
Reikvam, H., Dalgaard, J., Johansen, S., Tvedt, T. H. A., & Bruserud, Ø. (2019) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.18.0775 · Cited by 3
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review
Cortes, J. E., Candoni, A., Clark, R. E., Leber, B. F., Montesinos, P., Vyas, P., Zeidan, A. M., & Heuser, M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1817445 · Cited by 3
Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation
Ramsey, H. E., Stengel, K. R., Pino, J. C., Johnston, G., Childress, M. A., Gorska, A. E., Arrate, M. P., Fuller, L., Villaume, M. T., Fischer, M. A., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00830-5 · Cited by 3
Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia
Hershenfeld, S. A., Atenafu, E. G., Chan, S. M., Gupta, V. K., Maze, D. C., Schuh, A. C., Sibai, H. A., Yee, K. W. L., & Schimmer, A. D. (2023) · Acta Haematologica · doi:10.1159/000531484 · Cited by 3
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis
Li, X., Suh, H. S., Lachaîne, J., Schuh, A. C., Pratz, K. W., Betts, K. A., Song, J., Dua, A., & Bui, C. N. (2023) · Value in Health · doi:10.1016/j.jval.2023.09.001 · Cited by 4
Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high‐risk myelodysplastic syndromes
Izutsu, K., Ubukawa, K., Morishita, T., Onishi, Y., Ishizawa, K., Fujii, Y., Kimura, N., Yokochi, M., & Naoe, T. (2024) · Cancer Science · doi:10.1111/cas.16054 · Cited by 3
Primary Vaginal Chloroma: A Rare Case Report.
Madabhavi, I., Patel, A., Modi, M., Revannasiddaiah, S., & Chavan, C. (2018) · Europe PMC (PubMed Central) · Cited by 3
The artful management of older patients with acute myeloid leukemia
Yang, J., & Schiffer, C. A. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1153963 · Cited by 3
Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia
Minakata, D., Fujiwara, S., Ikeda, T., Toda, Y., Ito, S., Mashima, K., Umino, K., Nakano, H., Yamasaki, R., Morita, K., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2251-z · Cited by 3
The long road: improving outcome in elderly “unfit” AML?
Löwenberg, B., & Huls, G. A. (2020) · Blood · doi:10.1182/blood.2020005651 · Cited by 3
Toward a better management of older patients with acute myeloid leukemia
Liapis, K., & Cavenagh, J. D. (2015) · Future Oncology · doi:10.2217/fon.15.8 · Cited by 3
Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia
Wei, A. H., Roboz, G. J., & Kantarjian, H. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00080 · Cited by 3
Treatment of acute myeloid leukaemia
Burnett, A. K. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-6-s58 · Cited by 2
Self-citation
The safety of treatment options for elderly people with acute myeloid leukemia
Thomas, X., & Jeune, C. L. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1161020 · Cited by 2
Induction treatment of acute myeloid leukemia in an elderly patient with intramarrow injection/administration of cytarabine. Second case report
Islam, A. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1081 · Cited by 2
Treatment of AML in Older Patients
Hilberink, J. R., & Huls, G. A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94979 · Cited by 2
Pharmacoeconomic Analysis of Gilteritinib in the Therapy of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Mutation
Колбин, А. С., Gomon, Y. M., Balykina, Y. Е., & Proskurin, M. A. (2022) · Clinical oncohematology · doi:10.21320/2500-2139-2022-15-1-85-96 · Cited by 2
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm
Halpern, A. B., Othus, M. K. D., Alcorn, G., Ali, Z., Garcia, K. A., Percival, M. M., Keel, S., Cassaday, R. D., Becker, P. S., Estey, E. H., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01524-1 · Cited by 2
Consenso de leucemia mieloide aguda en México
Arana-Luna, L. L., Alvarado‐Ibarra, M., Silva-Michel, L. G., Morales-Maravilla, A., González-Rubio, M. D. C., Chavez-Aguilar, L. A., Tena-Iturralde, M. F., Mojica-Balderas, L., Zapata-Canto, N. P., Galindo-Delgado, P., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000597 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_48 · Cited by 2
Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia
Mudd, T. W., Diebold, K., Parks, K., Hardee, M., Jarodiya, J., Espinoza-Gutarra, M. R., Vachhani, P. J., Bachiashvili, K., Rangaraju, S., Mohty, R., et al. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107920 · Cited by 2
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML
Nier, S., Pelouchová, J., Hills, R., Salek, S., Derrien, H., Chatin, S., Bigne, A.-M. D. L., Vives, S., Récher, C., Döhner, H., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2587002 · Cited by 2
Self-citation
Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate
Arahata, M., Shimizu, Y., Asakura, H., & Nakao, S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0100-6 · Cited by 2
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia
Wei, A. H., & Tan, P. T. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.731604 · Cited by 2
Akute myeloische Leukämie
Staib, P., Lippl, S., & Spiekermann, K. (2015) · best practice onkologie · doi:10.1007/s11654-015-0247-9 · Cited by 2
Hypomethylating Agents in Oncohematology
Shirin, A. D., & Baranova, O. Y. (2016) · Clinical oncohematology · doi:10.21320/2500-2139-2016-9-4-369-382 · Cited by 2
Diagnostik und Therapie der akuten myeloischen Leukämie
Röllig, C. (2019) · best practice onkologie · doi:10.1007/s11654-019-0164-4 · Cited by 2

Authors: Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K.
Affiliations: Cardiff University (GB)
Heartlands Hospital (GB)
Derriford Hospital (GB)
University College Hospital (GB)
Belfast City Hospital (GB)
Cancer Research UK Clinical Trials Unit (GB)
Corresponding author: Burnett, Alan K.
ORCID: Burnett, Alan K.
Goldstone, Anthony H.
McMullin, Mary F.
Hills, Robert K.
Wheatley, Keith
Venue: Cancer
Publisher: Wiley
Published: 2007-02-21
Volume: 109
Issue: 6
Pages: 1114-1124
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.22496
OpenAlex: W2068556430
Cited by: 619
References: 26
Citations by year: 2026: 5 · 2025: 14 · 2024: 13 · 2023: 23 · 2022: 28 · 2021: 43 · 2020: 45 · 2019: 40 · 2018: 29 · 2017: 37 · 2016: 36 · 2015: 54 · 2014: 48 · 2013: 42 · 2012: 36
FWCI: 18.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Research Portal (Queen's University Belfast) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: acute myeloid leukemia, high-risk myelodysplastic syndrome, low-dose cytarabine, hydroxyurea, all-trans retinoic acid, elderly patients, complete remission, overall survival, adverse cytogenetics, best supportive care
MeSH terms: Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Risk, Survival, Tretinoin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks